CoChat

Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium

Open access

Published version of a preprint

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Purpose: The objective of this study was to assess the efficacy and safety of pembrolizumab in combination with standard carboplatin/paclitaxel in patients with advanced endometrial cancer. Patients and Methods: This single-arm, open-label, multicenter phase II study enrolled patients with RECIST measurable advanced endometrial cancer. Patients could have received ≤ 1 prior platinum-based regimen and ≤ one non-platinum chemotherapy. The primary endpoint was objective response rate (ORR). Planned sample size of 46 subjects provided 80% power to detect 15% ORR improvement compared with historical control rate of 50%. Results: A total of 46 patients were enrolled and 43 were evaluable for ORR. Median age was 66 (range: 43–86). Thirty-four (73.9%) patients had recurrent and 12 (26.1%) primary metastatic endometrial cancer. Patients received carboplatin AUC6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg i.v. every 3 weeks for up to six cycles. ORR was 74.4% (32/43), higher than historic controls (P = 0.001). Median progression-free survival (PFS) was 10.6 months (95% confidence interval, 8.3–13.9 months). The most common grade 1–2 treatment-related adverse event (TRAE) included anemia (56.5%), alopecia (47.8%), fatigue (47.8%), and neuropathy (13%), while the most common grade 3–4 TRAEs were lymphopenia, leukopenia, and anemia (19.6% each). High-dimensional spectral flow cytometry (CyTEK) identified enrichment in peripheral CD8+ and CD4+ T-cell populations at baseline in responders. The CD8+ T-cell compartment in responders exhibited greater expression levels of PD-1 and PD-L1 and higher abundance of effector memory CD8+ cells compared with nonresponders. Conclusions: Addition of pembrolizumab to carboplatin and paclitaxel for advanced endometrial cancer was tolerated and improved ORR compared with historical outcomes. Significance: The results of the study support that the combination of pembrolizumab with carboplatin and paclitaxel is well tolerated and active in patients with advanced endometrial cancer. The duration of response and the PFS were significantly longer in patients with mismatch repair deficient/microsatellite instability-high compared with mismatch repair proficient/microsatellite stable tumors. Responders to treatment tend to have enriched CD8+ T-cell and CD4+ T-cell populations among peripheral blood mononuclear cells at baseline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2767-9764.crc-22-0147

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Objective responses to treatment: Tumor percent change from baseline by MMR/MSI status (n = 40; A). B, Duration of overall response by MMR/MSI status (n = 28).
FIGURE 1 Objective responses to treatment: Tumor percent change from baseline by MMR/MSI status (n = 40; A). B, Duration of overall response by MMR/MSI status (n = 28).CC BY · PubMed Central
FIGURE 2 PFS: PFS was calculated by Kaplan–Meier method (n = 46; A). B, PFS by MMR/MSI status (n = 40).
FIGURE 2 PFS: PFS was calculated by Kaplan–Meier method (n = 46; A). B, PFS by MMR/MSI status (n = 40).CC BY · PubMed Central
FIGURE 3 Swimmer Plot Illustrates PFS and duration of response for each patient by MMR/MSI status (n = 43). Green corresponds to MMR deficient, blue to MMR proficient and gray indicates unknown MMR status.
FIGURE 3 Swimmer Plot Illustrates PFS and duration of response for each patient by MMR/MSI status (n = 43). Green corresponds to MMR deficient, blue to MMR proficient and gray indicates unknown MMR status.CC BY · PubMed Central
FIGURE 4 Identification of differences in PBMC subsets from responders and nonresponder patients before treatment using spectral cytometry. A, Exemplified GPU-tSNE visualization of overlaid cell population composition in the PBMC from nonresponders (n = 6) and responders (n = 17) before the initiation of therapy (C1D1). B, Summarized frequencies of total main immune cell populations among live PBMC from nonresponders or responders at C1D1 and 30 days after treatment. C, The expression levels of CD274 and CD279 were compared in peripheral CD8+ T cells between nonresponders and responders at C1D1. D, Exemplified GPU-tSNE visualization of overlaid memory subset composition in peripheral CD8+ and CD4+ T cells from nonresponders and responders at C1D1. E, EdgeR analysis identified the CD8+ EM cell subset with significant differences in relative abundance between nonresponders and responders at C1D1. Error bars represent mean with SEM. *, P < 0.05. All P values were calculated using two-sided t tests and were corrected for the multiple comparisons using the Benjamini–Hochberg adjustment.
FIGURE 4 Identification of differences in PBMC subsets from responders and nonresponder patients before treatment using spectral cytometry. A, Exemplified GPU-tSNE visualization of overlaid cell population composition in the PBMC from nonresponders (n = 6) and responders (n = 17) before the initiation of therapy (C1D1). B, Summarized frequencies of total main immune cell populations among live PBMC from nonresponders or responders at C1D1 and 30 days after treatment. C, The expression levels of CD274 and CD279 were compared in peripheral CD8+ T cells between nonresponders and responders at C1D1. D, Exemplified GPU-tSNE visualization of overlaid memory subset composition in peripheral CD8+ and CD4+ T cells from nonresponders and responders at C1D1. E, EdgeR analysis identified the CD8+ EM cell subset with significant differences in relative abundance between nonresponders and responders at C1D1. Error bars represent mean with SEM. *, P < 0.05. All P values were calculated using two-sided t tests and were corrected for the multiple comparisons using the Benjamini–Hochberg adjustment.CC BY · PubMed Central
FIGURE 5 Identification of metaclusters in PBMC with significant differences between responders and nonresponders before treatment. A, Exemplified GPU-tSNE visualization of overlaid unsupervised metaclusters in PBMC using the FlowSOM algorithm from nonresponders (n = 6) and responders (n = 17) at C1D1 prior to therapy. B, EdgeR analysis identified metaclusters with significant differences in relative abundance between nonresponders and responders. C, The heat map represents the median expression levels of indicated markers within the metaclusters having significant differences in relative abundance between nonresponders and responders at C1D1. D, Relative expression levels of CD279 in the metaclusters of 6 and 12 were significantly different between nonresponders and responders at C1D1 based on the SAM analysis (Padjusted < 0.05).
FIGURE 5 Identification of metaclusters in PBMC with significant differences between responders and nonresponders before treatment. A, Exemplified GPU-tSNE visualization of overlaid unsupervised metaclusters in PBMC using the FlowSOM algorithm from nonresponders (n = 6) and responders (n = 17) at C1D1 prior to therapy. B, EdgeR analysis identified metaclusters with significant differences in relative abundance between nonresponders and responders. C, The heat map represents the median expression levels of indicated markers within the metaclusters having significant differences in relative abundance between nonresponders and responders at C1D1. D, Relative expression levels of CD279 in the metaclusters of 6 and 12 were significantly different between nonresponders and responders at C1D1 based on the SAM analysis (Padjusted < 0.05).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 10

Metadata

Authors
Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., & Matei, D.
Affiliations
  • Northwestern University (US)
  • 4Ironwood Cancer and Research Centers, Gilbert, Arizona.
  • Indiana University Indianapolis (US)
  • University of Iowa Hospitals and Clinics (US)
  • University of Minnesota (US)
  • 8Department of Preventive Medicine, Northwestern University, Chicago, Illinois.
Corresponding author
  • Zhang, Bin
  • Matei, Daniela
Venue
Cancer Research Communications
Published
2022-10-28
Volume
2
Issue
10
Pages
1293-1303
ISSN
2767-9764 (ISSN-L)
OpenAlex
W4293010058
Cited by
9
References
52
Citations by year
2025: 4 · 2024: 2 · 2023: 3
FWCI
2.27
Type
journal article
Language
en
Open access
Locations
  • Cancer Research Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
Funders
  • HHS | National Institutes of Health (K12 HD050121)
  • HHS | NIH | National Cancer Institute (CA208354, CA222963, CA250101)
  • Big Ten Research Consortium
  • GOG Foundation
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
endometrial adenocarcinoma, pembrolizumab, chemoimmunotherapy, carboplatin, paclitaxel, PD-1 inhibitors, objective response rate, progression-free survival, CD8+ T cells, PD-L1 expression, PD-1, treatment-related adverse events, immunotherapy biomarkers, recurrent endometrial cancer, metastatic endometrial cancer
MeSH terms
Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Female, Humans, Lung Neoplasms, Carboplatin, Endometrial Neoplasms, Paclitaxel

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. https://app.cochat.ai/papers/10.1158/2767-9764.crc-22-0147
The paper
Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., & Matei, D. (2022). Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-22-0147

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.